CDK4 and breast carcinoma: Particularly, the cyclin-dependent kinase (CDK)4/6-retinoblastoma pathway has been implicated in the progression of breast cancer, and some TNBC cell lines have demonstrated sensitivity to the use of CDK4/6 inhibitors [74].